Skip to main content

Table 1 Patient demographics and baseline disease state

From: Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial

  Baseline Hemoglobin < 10 g/dL Baseline Hemoglobin ≥10 g/dL
  Darbepoetin alfa 500 mcg Q3W
N = 176
Darbepoetin alfa 2.25 mcg/kg QW
N = 175
Total
N = 351
Darbepoetin alfa 500 mcg Q3W
N = 177
Darbepoetin alfa 2.25 mcg/kg QW
N = 177
Total
N = 354
Sex, n (%)       
   Female 93 (53) 97 (55) 190 (54) 93 (53) 100 (56) 193 (55)
Age, years       
   Median (Min, Max) 59 (20, 86) 61 (20, 83) 60 (20, 86) 61 (20, 85) 60 (21, 84) 60.5 (20, 85)
   ≥65, n (%) 59 (34) 65 (37) 124 (35) 65 (37) 65 (37) 130 (37)
   ≥75, n (%) 15 (9) 14 (8) 29 (8) 19 (11) 12 (7) 31 (9)
Tumor type, n (%)       
   Large Intestine/Colon 30 (17) 16 (9) 46 (13) 35 (20) 35 (20) 70 (20)
   Breast 23 (13) 27 (15) 50 (14) 34 (19) 28 (16) 62 (18)
   NSCLC 17 (10) 15 (9) 32 (9) 17 (10) 17 (10) 34 (10)
Disease stage at diagnosis, n (%)       
   I 13 (7) 10 (6) 23 (7) 15 (8) 8 (5) 23 (6)
   II 25 (14) 38 (22) 63 (18) 40 (23) 37 (21) 77 (22)
   III 53 (30) 49 (28) 102 (29) 42 (24) 44 (25) 86 (24)
   IV 74 (42) 62 (35) 136 (39) 59 (33) 71 (40) 130 (37)
   Other/Missing or Unknown 11 (6) 16 (9) 27 (8) 21 (12) 17 (10) 38 (11)
Prior chemotherapy, n (%) 169 (96) 153 (87) 322 (92) 162 (92) 154 (87) 316 (89)
Prior platinum chemotherapy, n (%) 68 (39) 59 (34) 127 (36) 59 (33) 63 (36) 122 (34)
Prior radiotherapy, n (%) 60 (34) 47 (27) 107 (30) 61 (34) 56 (32) 117 (33)
Prior erythropoietic therapy, n (%)a 21 (12) 21 (12) 42 (12) 18 (10) 13 (7) 31 (9)
Baseline hemoglobin, g/dL       
   Mean (SD) 9.01 (0.78) 9.09 (0.64) 9.05 (0.71) 10.50 (0.29) 10.46 (0.30) 10.48 (0.30)
   Median (Min, Max) 9.20 (5.9, 9.9) 9.20 (6.8, 9.9) 9.20 (5.9, 9.9) 10.50 (10.0, 10.9) 10.50 (10.0, 11.8) 10.50 (10.0, 11.8)
  1. Q3W = every three weeks; QW = weekly; Min = minimum; Max = maximum; NSCLC = non-small cell lung cancer; SD = standard deviation
  2. aPrior erythropoietic agents were not administered within 4 weeks of study day 1.